NVO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	1.79M
Gjennomsnittsvolum	5.00M
Markedsverdi	557.99B
EPS	$0 ( 2024-01-31 )
Neste inntjeningsdato	( $0.770 ) 2024-05-02
Last Dividend	$0.884 ( 2023-08-18 )
Next Dividend	$0 ( N/A )
P/E	47.34
ATR14	$0.0490 (0.04%)

Volum Korrelasjon

Lang: 0.28 (neutral)

Kort: -0.22 (neutral)

Signal:(50.785) Neutral

Novo Nordisk A/S Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Novo Nordisk A/S Korrelasjon - Valuta/Råvare

0.31
( neutral )

0.28
( neutral )

0.00
( neutral )

0.45
( neutral )

0.37
( neutral )

0.31
( neutral )

Novo Nordisk A/S Økonomi

Annual	2023
Omsetning:	$232.26B
Bruttogevinst:	$196.50B (84.60 %)
EPS:	$18.67

FY	2023
Omsetning:	$232.26B
Bruttogevinst:	$196.50B (84.60 %)
EPS:	$18.67

FY	2022
Omsetning:	$176.95B
Bruttogevinst:	$148.51B (83.92 %)
EPS:	$12.26

FY	2021
Omsetning:	$140.80B
Bruttogevinst:	$117.14B (83.20 %)
EPS:	$20.46

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.584 (N/A)	$0 (N/A)	$1.189 (N/A)	$0 (N/A)	$0.884 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.78 - good (77.78%) | Divividend Growth Potential Score: 5.60 - Stable (12.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.000600	1982-04-23
Last Dividend	$0.884	2023-08-18
Next Dividend	$0	N/A
Payout Date	2023-08-29
Next Payout Date	N/A
# dividends	53	--
Total Paid Out	$15.84	--
Avg. Dividend % Per Year	2.26%	--
Score	4.44	--
Div. Sustainability Score	7.78
Div.Growth Potential Score	5.60
Div. Directional Score	6.69	--

Next Divdend (Est)
(2024-05-27)

$0.906 Estimate 6.52 %

Dividend Stability

0.26 Very Poor

Dividend Score

4.44

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1982	$0.000600	0.30%
1983	$0.00274	1.29%
1984	$0.00288	1.02%
1985	$0.00259	2.18%
1986	$0.00344	2.37%
1987	$0.00414	2.50%
1988	$0.00522	4.51%
1989	$0.00463	2.39%
1990	$0.00624	2.51%
1991	$0.00509	1.64%
1992	$0.00600	1.32%
1993	$0.00540	1.22%
1994	$0.0112	2.26%
1995	$0.00840	1.80%
1996	$0.0158	2.26%
1997	$0.0112	1.24%
1998	$0.0161	1.13%
1999	$0.0164	1.17%
2000	$0.0422	3.13%
2001	$0.0318	1.79%
2002	$0.0369	1.84%
2003	$0.0523	3.56%
2004	$0.0745	3.62%
2005	$0.0840	3.17%
2006	$0.0966	3.39%
2007	$0.122	2.93%
2008	$0.177	2.77%
2009	$0.207	3.92%
2010	$0.281	4.28%
2011	$0.364	3.27%
2012	$0.499	4.26%
2013	$0.637	3.84%
2014	$0.830	4.52%
2015	$0.760	3.58%
2016	$1.411	4.92%
2017	$1.137	6.33%
2018	$1.137	4.20%
2019	$1.238	5.29%
2020	$1.301	4.46%
2021	$1.506	4.22%
2022	$1.620	2.98%
2023	$2.07	3.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.360	1.500	2.79	4.19	[0 - 0.5]
returnOnAssetsTTM	0.266	1.200	1.130	1.356	[0 - 0.3]
returnOnEquityTTM	0.905	1.500	1.056	1.585	[0.1 - 1]
payoutRatioTTM	0.380	-1.000	6.20	-6.20	[0 - 1]
currentRatioTTM	0.823	0.800	-0.884	-0.708	[1 - 3]
quickRatioTTM	0.622	0.800	-1.048	-0.839	[0.8 - 2.5]
cashRatioTTM	0.0848	1.500	-0.640	-0.960	[0.2 - 2]
debtRatioTTM	0.0859	-1.500	8.57	-10.00	[0 - 0.6]
interestCoverageTTM	69.78	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
freeCashFlowPerShareTTM	15.68	2.00	2.16	4.32	[0 - 20]
debtEquityRatioTTM	0.253	-1.500	8.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.846	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.442	1.000	3.17	3.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.739	0.800	8.41	6.73	[0.5 - 2]
Total Score				7.78

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.05	1.000	5.35	0	[1 - 100]
returnOnEquityTTM	0.905	2.50	4.25	1.585	[0.1 - 1.5]
freeCashFlowPerShareTTM	15.68	2.00	4.77	4.32	[0 - 30]
dividendYielPercentageTTM	0.206	1.500	4.86	0	[0 - 0.4]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
payoutRatioTTM	0.380	1.500	6.20	-6.20	[0 - 1]
pegRatioTTM	0.909	1.500	7.27	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.469	1.000	0.777	0	[0.1 - 0.5]
Total Score				5.60

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sanntidsoppdatering for Novo Nordisk A/S [NVO]

Upcoming Earnings Alert

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)